
What We're Reading: Theranos Now Subject of a Criminal Investigation
What we're reading, April 19, 2016: blood-testing laboratory Theranos is now facing a criminal investigation; biosimilars may not be cheaper than brand name biologics for some seniors; and stigma and misconceptions remain regarding palliative care.
Blood-testing laboratory Theranos is now facing a criminal investigation. The company has come under scrutiny recently with questions about whether Theranos’ technology, which could perform blood tests from a single finger prick, actually worked. Now,
Biosimilars are expected to lower the cost of medication, but not for some due to an “unintended consequence” of the Affordable Care Act (ACA). Instead, Medicare Part D beneficiaries will pay more for biosimilars than they would for more expensive brand name biologics,
Stigma remains an issue for patients with cancer who could benefit from palliative care. A Canadian study found that patients turn down palliative care because they think it is akin to giving up and waiting to die,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.